论文部分内容阅读
摘译:无论是医学专业人士还是大众媒体都对肿瘤药物的昂贵价格提出了批评。在美国,现在一种新的肿瘤药物一年的平均治疗费用超过10万美元,然而疗效却不尽人意,大多新药与“老药”相比仅能延长肿瘤患者中位生存期数周到数月,显然性价比太低。制药公司为了保护昂贵药物的市场占有率,也会影响药物疗效性价比临床试验的开展。2011年美国食品和药物管理局(FDA)基于三期随机临床试验数据结果,批准了阿比特龙用于曾接受
Excerpt: Both medical professionals and the mass media have criticized the high cost of oncology drugs. In the United States, for example, a new oncology drug now costs more than $ 100,000 a year on average, but its efficacy is less than satisfactory. Most new drugs only prolong the median survival of cancer patients by several weeks A few months, apparently cost is too low. Pharmaceutical companies in order to protect the market share of expensive drugs, will also affect the efficacy of drug efficacy of clinical trials carried out. 2011 US Food and Drug Administration (FDA) based on the results of three randomized clinical trial data, approved the abiraterone used to have accepted